These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 17324578)

  • 1. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
    Khalil MY; Grandis JR; Shin DM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM; Allen GW; Bonner JA
    J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
    Lage A; Crombet T; González G
    Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
    Harari PM; Huang S
    Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
    Wheatley-Price P; Shepherd FA
    Curr Opin Oncol; 2008 Mar; 20(2):162-75. PubMed ID: 18300766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R; Troiani T; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR as a target: rationale for therapy.
    Wujcik D
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor: a promising target in solid tumours.
    Laskin JJ; Sandler AB
    Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
    Ettinger DS
    Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J; Baselga J
    Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.